StockNews.com Initiates Coverage on NeuroMetrix (NASDAQ:NURO)

Investment analysts at StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report issued on Friday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Trading Up 0.7 %

Shares of NeuroMetrix stock opened at $4.21 on Friday. The firm has a market capitalization of $8.59 million, a PE ratio of -0.92 and a beta of 2.20. NeuroMetrix has a 12 month low of $2.66 and a 12 month high of $4.73. The business’s 50-day moving average price is $4.04 and its 200-day moving average price is $3.90.

NeuroMetrix (NASDAQ:NURO) last announced its quarterly earnings data on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share for the quarter. The business had revenue of $0.59 million during the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. During the same period last year, the firm posted ($1.66) EPS.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.